
# PATIENT-DERIVED MICROTUMORS





PDMs retain original tissue's histological characteristics

PTT PDM

| 100 µm | 26 | 100 µ

We provide a versatile immuno-oncology testing platform powered by patient-derived microtumors (PDMs) and autologous immune cells (TILs, PBMCs) — for evaluating drug candidates, immunotherapies, and combination treatments.

### **Characteristics**


- Retention of primary tumor tissue histology, no artificial ECM
- Real autologous co-culture models employing TILs or PBMC-derived lymphocytes
- Modeling of various types of solid tumors is available


### **Services**

- Next-level drug & ATMP testing
- Full patient consent and FTO for commercial studies
- Seamless access to comprehensive in-house downstream analysis portfolio




High-end confocal microscopy with up to 4D imaging and controlled environmental conditions tracks T-cell infiltration and assesses microtumor integrity and viability.





# Analysis portfolio

- Viability and toxicity
- Tumor-specific apoptosis
- Presence of therapeutic targets and cell surface markers
- Cytokine release
- T-cell infiltration
- Tumor-specific protein expression and activation signatures



## CONTACT US FOR MORE DETAILS!



### Dr. Martin Kriebel Phone +49 7121 51530-810 martin.kriebel@nmi.de

### ABOUT THE NMI

The NMI is a non-university research institution that conducts application-oriented research in the biological and material sciences. It has an interdisciplinary range of expertise in R&D and services for companies in the healthcare, automotive, mechanical engineering, and toolmaking industries. The NMI cooperates with top-class institutions in its research activities. It is supported by the Baden-Württemberg Ministry of Economic Affairs and is a member of innBW.

NMI Natural and Medical Sciences Institute at the University of Tübingen

Markwiesenstraße 55 72770 Reutlingen Phone +49 7121 51530-0 info@nmi.de www.nmi.de/en/







